Shigella News and Research

RSS

Novel ingestible device enables non-invasive profiling of the gut microbiome, proteome, and metabolome

Researchers developed an ingestible device to collect samples from the human intestine.

12 May 2023

Breast milk microbes shape infant gut health

Research investigates the association between the microbial communities in human milk and infant gut. The study found that milk microbial communities have a long-term effect on the infant gut microbiome both through sharing of microbes and other molecular mechanisms.

9 May 2023

The international spread of drug-resistant Shigella sonnei

Researchers examined the international dissemination of the outbreak of extensively drug-resistant Shigella sonnei.

12 Apr 2023

What are the effects of kimchi on human health?

Researchers evaluated the effectiveness of kimchi consumption on overall human health.

4 Apr 2023

Fighting antibiotic-resistant "superbugs" with viruses

The Centers for Disease Control and Prevention warns that the increase in cases of the drug-resistant bacterial infection Shigella could be a predictor of what's to come for other bacteria.

21 Mar 2023

Increase in resistant Shigella infections among men who have sex with men

Researchers report a rise in Shigella flexneri type 2a infections in men who have sexual intercourse with men in England from September 2021 onward.

7 Feb 2023

What do gut microbiota have to do with Alzheimer's and dementia?

Researchers explore the preventive and therapeutic potential of gut microbiome modulation in the treatment of Alzheimer’s disease.

6 Feb 2023

Trends in antibiotic resistance for the priority bacterial pathogens in children and adults

Researchers assessed the variation in antibiotic resistance patterns in adults and children.

5 Jan 2023

Study demonstrates safety and efficacy of a three-dose whole-parasite vaccine against malaria

A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa, which has endemic malaria.

4 Jan 2023

Bacterial outer membrane vesicles: utility as vaccines and novel engineering approaches

Scientists have described the utility of gram-negative bacteria-derived outer membrane vesicles as vaccines and methods to expand their applications.

3 Jan 2023

Immune-evading Mycobacterium tuberculosis prevents inflammatory responses by hijacking the host’s ubiquitin

A new study discussed the findings of Chai et al., which revealed that triple specificity protein phosphatase (ptpB) secreted by Mycobacterium tuberculosis inhibits pyroptosis and the release of cytokines by macrophages, allowing M. tuberculosis to invade the immune system.

19 Dec 2022

Zebrafish models shed light on Shigella infection

In this interview, NewsMedical speaks with Professor Serge Mostowy and Sydney Miles about their research on bacterial infection, and, in particular, on Shigella Flexneri and enteropathogens.

From IDEA Bio-Medical Ltd. 6 Dec 2022

IVI and Lemonex sign MOU to join forces on vaccine development

The International Vaccine Institute announced on November 10 it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.

10 Nov 2022

Lower risk of colorectal cancer associated with dietary flavanone and anthocyanidin intake, according to new research

In a new study, researchers assessed the risk of colorectal cancer (CRC) with the intake of flavonoids.

31 Oct 2022

How does the human gut microbiome impact menopause?

A recent study summarizes available information on the relationship between menopause and the gut microbiome.

24 Aug 2022

A low-energy, high FODMAP diet in prediabetes and diabetes?

Researchers summarize the available knowledge on FODMAPs and suggest that they can play a role in the prevention and treatment of diabetes.

10 Aug 2022

IVI successfully completes the '2022 Introductory Course for Biologics Development and Manufacturing'

The International Vaccine Institute (IVI) successfully completed the '2022 Introductory Course for Biologics Development and Manufacturing' on July 29 to train 106 participants from 24 low- and middle-income countries (LMICs) and 32 from the Republic of Korea.

29 Jul 2022